Clinical Genomics Announces Implementation of UNIConnect pMDx™ LIMS
News Jun 03, 2016
Clinical Genomics has announced that it has signed an agreement with UNIConnect LC to implement the company’s Precision Molecular Diagnostics (pMDx™) laboratory information management system (LIMS) in its two laboratories. The software system will facilitate comprehensive automation of all laboratory processes from sample accessioning through final clinical result reporting.
Following an extensive evaluation period, Clinical Genomics selected pMDx based on the system’s fundamental focus on the needs and processes of the molecular diagnostics laboratory and the key quality and operational checks integrated in the LIMS software.
“As a rapidly expanding biotechnology company, we sought a laboratory software provider with proven expertise in the specialized molecular diagnostics space that would have the scale and flexibility to adapt to our needs over time,” said Lawrence LaPointe, Ph.D., President and CEO of Clinical Genomics. “We are confident that the pMDx platform will support our goals by enabling rapid specimen turnaround times, while ensuring high levels of accuracy and automation.”
Clinical Genomics plans to implement pMDx in its molecular diagnostics laboratories in Bridgewater, New Jersey and Sydney, Australia. Dr. LaPointe stated that, “As a growing global company, we value the ability of the pMDx platform to provide our labs with a consistent LIMS in the various markets where we currently operate and also where we anticipate future expansion.”
William S. Harten, UNIConnect Founder and CEO, noted, "Clinical Genomics’ blood-based colorectal cancer detection test has demonstrated strong potential to improve how the disease is currently monitored and managed. We are proud to announce our technology partnership and look forward to supporting their continued growth in the emerging liquid biopsy space. We’re particularly pleased that this relationship will introduce pMDx into the Australia/New Zealand market; UNIConnect systems are already utilized in North America, with deployments in Europe, Asia and Africa. Our relationship with Clinical Genomics will provide local exposure to a robust and growing life sciences community.”
In of organic chemistry, reactions are notoriously difficult to analyze. As a result, reaction data in chemoinformatics has been much less developed than information about single molecules. In a new project, titled CGRtools, researchers solved a number of problems to better handle reaction information. The software library is significantly richer in functionality than all the existing tools.READ MORE